Segment Data (Schedule of Segment Reporting Information by Business Segment) (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jun. 28, 2019	Jun. 29, 2018	Jun. 28, 2019	Jun. 29, 2018
Net sales		$ 823.3	$ 825.5	$ 1,613.9	$ 1,580.8
Operating Income (Loss)	[1]	(29.9)	52.7	(14.5)	78.8
Intangible asset amortization		(216.6)	(184.3)	(439.4)	(362.3)
Restructuring and related charges, net		0.2	(58.8)	(4.0)	(87.0)
Non-restructuring impairment charge		(113.5)	0.0	(113.5)	0.0
Specialty Brands
Restructuring and related charges, net		0.1	(47.0)	(0.4)	(47.5)
Operating Segments
Operating Income (Loss)		355.3	308.3	655.2	584.6
Operating Segments | Specialty Brands
Net sales		627.8	631.7	1,232.0	1,204.3
Operating Income (Loss)		321.4	265.2	596.9	506.4
Operating Segments | Specialty Generics
Net sales		195.5	193.8	381.9	376.5
Operating Income (Loss)		33.9	43.1	58.3	78.2
Corporate, Non-Segment
Corporate and unallocated expenses	[2]	(36.4)	(12.5)	(82.2)	(56.5)
Intangible asset amortization		(216.6)	(184.3)	(439.4)	(362.3)
Restructuring and related charges, net		0.2	(58.8)	(4.0)	(87.0)
Non-restructuring impairment charge		(113.5)	0.0	(113.5)	0.0
Separation Costs	[3]	$ (18.9)	0.0	$ (30.6)	0.0
Sucampo [Member]
Operating Income (Loss)			37.0		67.7
Intangible asset amortization			(17.9)		(27.0)
Cost of Sales [Member] | Sucampo [Member]
Amortization Of Inventory Step-Up To Cost Of Sales			$ 31.5		$ 46.5

[1] The amount of operating loss included in the Company's unaudited condensed consolidated statement of income for the three and six months ended June 29, 2018 related to the Sucampo Acquisition was $37.0 million and $67.7 million, respectively. Included within these results were $17.9 million and $27.0 million of amortization associated with intangibles recognized from this acquisition and $31.5 million and $46.5 million of expense associated with fair value adjustments of acquired inventory for the three and six months ended June 29, 2018, respectively.

[2] Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segment.

[3] Represents costs incurred related to the separation of the Company's Specialty Generics segment, inclusive of rebranding costs, which are included in SG&A.